Aggregated Tau activates NLRP3-ASC inflammasome exacerbating exogenously seeded and non-exogenously seeded Tau pathology in vivo.
Stancu IC, Cremers N, Vanrusselt H, Couturier J, Vanoosthuyse A, Kessels S, Lodder C, Brône B, Huaux F, Octave JN, Terwel D, Dewachter I. · 2019
Read Aggregated Tau activates NLRP3-ASC inflammasome exacerbating exogenously seeded and non-exogenously seeded Tau pathology in vivo. by Stancu IC, Cremers N, Vanrusselt H, Couturier J, Vanoosthuyse A, Kessels S, Lodder C, Brône B, Huaux F, Octave JN, Terwel D, Dewachter I. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6426830.txt.
Introduction
Stancu and co-authors test whether clumped Tau protein switches on the NLRP3-ASC inflammasome, an immune alarm already tied to amyloid damage in Alzheimer's disease. Tau tangles spread through the brain in a prion-like way as seeds template new clumps. Whether those seeds also drive inflammation was unknown.
Tau seeds taken up by microglia did activate the inflammasome in culture. In Tau transgenic mice, lacking ASC sharply reduced seeded Tau pathology, and the NLRP3 blocker MCC950 had the same effect when given into the brain. Even unseeded Tau disease eased without ASC. Blocking this immune pathway could therefore slow three harmful processes at once.
Catalog record
| CREATOR | Stancu IC, Cremers N, Vanrusselt H, Couturier J, Vanoosthuyse A, Kessels S, Lodder C, Brône B, Huaux F, Octave JN, Terwel D, Dewachter I. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 86 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Aggregated Tau activates NLRP3–ASC inflammasome exacerbating exogenously seeded and non-exogenously seeded Tau pathology in vivo By Ilie-Cosmin Stancu, Niels Cremers, Hannah Vanrusselt, Julien Couturier, Alexandre Vanoosthuyse, Sofie Kessels, Chritica Lodder, Bert Brône, François Huaux, Jean-Noël Octave, Dick Terwel, Ilse Dewachter Published in: Acta Neuropathologica DOI: 10.1007/s00401-018-01957-y ABSTRACT Brains of Alzheimer’s disease patients are characterized by the presence of amyloid plaques and neurofibrillary tangles, both invariably associated with neuroinflammation. A crucial role for NLRP3–ASC inflammasome [NACHT, LRR and PYD domains-containing protein 3 (NLRP3)–Apoptosis-associated speck-like protein containing a CARD (ASC)] in amyloid-beta (Aβ)-induced microgliosis and Aβ pathology has been unequivocally identified. Aβ aggregates activate NLRP3–ASC inflammasome (Halle et al. in Nat Immunol 9:857–865, 2008) and conversely NLRP3–ASC inflammasome activation exacerbates amyloid pathology in vivo (Heneka et al. in Nature 493:674–678, 2013), including by prion-like ASC-speck cross-seeding (Venegas et al. in Nature 552:355–361, 2017). However, the link between inflammasome activation, as crucial sensor of innate immunity, and Tau remains unexplored. Here, we analyzed whether Tau aggregates acting as prion-like Tau seeds can activate NLRP3–ASC inflammasome. We demonstrate that Tau seeds activate NLRP3–ASC-dependent inflammasome in primary microglia, following microglial uptake and lysosomal sorting of Tau seeds. Next, we analyzed the role of inflammasome activation in prion-like or templated seeding of Tau pathology and found significant inhibition of exogenously seeded Tau pathology by ASC deficiency in Tau transgenic mice. We furthermore demonstrate that chronic intracerebral administration of the NLRP3 inhibitor, MCC950, inhibits exogenously seeded Tau pathology. Finally, ASC deficiency also decreased non-exogenously seeded Tau pathology in Tau transgenic mice. Overall our findings demonstrate that Tau-seeding competent, aggregated Tau activates the ASC inflammasome through the NLRP3–ASC axis, and we demonstrate an exacerbating role of the NLRP3–ASC axis on exogenously and non-exogenously seeded Tau pathology in Tau mice in vivo. The NLRP3–ASC inflammasome, which is an important sensor of innate immunity and intensively explored for its role in health and disease, hence presents as an interesting therapeutic approach to target three crucial pathogenetic processes in AD, including prion-like seeding of Tau pathology, Aβ pathology and neuroinflammation. Electronic supplementary material The online version of this article (10.1007/s00401-018-01957-y) contains supplementary material, which is available to authorized users. INTRODUCTION Brains of Alzheimer’s disease patients are characterized by the presence of amyloid plaques and neurofibrillary tangles, respectively composed of Aβ peptides and hyperphosphorylated Tau, and both invariably associated with neuroinflammatory changes [85, 86]. Genetic evidence, biomodelling data and biomarker analysis support an initiating role of accumulating Aβ in the pathogenetic process in EOFAD and sporadic AD patients [39, 47, 48]. While accumulating Aβ presents as a key initiator, but difficult disease-modifying target, there is a growing focus on multi-targeted strategies aiming at including key pathogenetic targets downstream of Aβ, which include Tau [11, 57] and its prion-like or templated propagation and neuroinflammatory changes [40, 64, 80, 99] as key pathogenetic processes in AD. An executive role of Tau in the pathogenetic process of AD and related Tauopathies is substantiated by (i) the existence of a family of neurodegenerative disorders all characterized by Tau-aggregation, by (ii) the identification of MAPT mutations autosomal dominantly linked to these Tauopathies, indicating that Tau dysfunction causes neurodegeneration, and by (iii) the strong correlation of progression of Tau pathology with progression of disease symptoms in AD—generally considered as a secondary Tauopathy [9, 11, 85, 92]. Furthermore, (iv) prion-like or templated propagation of Tau pathology has been consistently and reproducibly shown in in vitro and in vivo models, highlighting a self-propagating effect of Tau pathology once initiated [3, 12, 24–26, 30–33, 36, 37, 44, 49, 50, 56, 62, 77, 84, 89, 96, 97]. Prion-like propagation of Tau pathology thereby presents as a compelling mechanism for the progressive and characteristic development of Tau pathology, remarkably strong correlated with symptom progression in AD. Importantly, the presence of Tau seeds has been demonstrated not only in brains of Tau transgenic mice, but also in brains of patients [26, 45, 52] using a sensitive Tau seeding detector assay. This not only highlights the relevance of this process in human AD brains [75] but also emphasizes the interest to identify mechanisms to inhibit or target templated propagation of Tau pathology. Hence, the molecular and cellular processes involved in seeding and spreading of Tau pathology and their modulators present a topic of high interest, and represent highly interesting therapeutic targets. Brains of AD patients and patients with Tauopathies are invariably characterized by neuroinflammatory changes, raising a keen interest in their contribution to the pathogenetic process. Neuroinflammation and innate immunity, in particular, are hence increasingly investigated for their translational potential in neurodegenerative disorders including AD [40, 41, 74, 80]. Innate immunity and inflammasome are crucial in health and disease and, therefore, very intensively investigated [40, 41, 59–61, 66, 80]. The inflammasomes are the sensors of the innate immune system and induce inflammation in response to infectious ‘attacks’ [35] recognized by danger-associated signals [pathogen-associated molecular patterns (PAMPS) and danger-associated molecular patterns (DAMPS)] [40, 41, 59–61, 66, 80]. Inflammasome becomes activated by a dual stimuli leading to the activation of pattern recognition receptors (PRRs), including NOD-like receptors or NLRs. The NLRP3 inflammasome can be activated by structurally diverse stimuli including ATP, imidazoquinoline derivatives, various crystals as well as by bacterial toxins and also Aβ peptides displaying an amyloid structure [21, 51, 70, 72, 76]. NLRP3 activation induces heteromer formation or aggregation of ASC, leading to caspase-1 activation [35], which subsequently can cleave pro-interleukin-1 beta (pro-IL-1β) to active IL-1β. NLRP3–ASC inflammasome activation induces an increase in cytokine and chemokine concentrations and microglial activation, while its activation can also induce microglial death through pyroptosis [43]. Elegant work demonstrated that aggregated Aβ displaying amyloid structure [38, 55] activates the NLRP3–ASC inflammasome, following endo-lysosomal uptake and damage [38], resulting in the activation of caspase-1, subsequent cleavage of pro-IL-1β to IL-1β, and microglial activation [38]. NLRP3 inflammasome assembly was subsequently demonstrated to actively contribute to amyloid pathology [42, 95]. Heneka et al. elegantly demonstrated that inflammasome inhibition through NLRP3 or caspase-1 deficiency inhibits amyloid pathology in APP/PS1 transgenic mice [42, 95], with alterations in microglial phenotypes and phagocytosis capacity as potential contributing mechanisms. These findings were further confirmed using pharmacological NLRP3 inhibitors [16, 19]. Interestingly, ASC specks—fibrillar ASC aggregates formed upon inflammasome activation—have been shown to be released following inflammasome activation and to be taken up by ‘receptor’ microglial cells thereby contributing to the prion-like propagation of inflammasome activation [10, 23] and microglial activation in a prion-like way. This is particularly interesting in the context of prion-like propagation in AD and related neurodegenerative disorders. Venegas et al. demonstrated that aggregation of ASC into prion-like ASC specks exacerbated amyloid pathology [95], by a cross-seeding mechanism. While the relation between Aβ and inflammasome has been analyzed in exquisite detail, the relation between inflammasome and Tau and prion-like propagation of Tau pathology remains unexplored. Neuropathological and imaging studies have revealed microglial changes associated with Tau pathology in brains of primary Tauopathy patients and animal models recapitulating Tau pathology. It must be noted that neuroinflammatory changes are a prominent characteristic of Tauopathies per se, also in the absence of amyloid plaque pathology, highlighting the association between Tau pathology and microglial changes [5, 18, 46, 64, 86, 90, 100]. This has been demonstrated in postmortem brain tissue